Product Name:
CDKL2-CT
Product Number:
ab-nk261-1
Target Full Name: Cyclin-dependent kinase-like 2; Serine/threonine protein kinase KKIAMRE
Target Alias: Kinase CDKL2; KKIAMRE; P56; Protein kinase p56 KKIAMRE; Serine/threonine-protein kinase KKIAMRE
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK261-1
Antibody Target Type: Pan-specific
Protein UniProt: Q92772
Protein SigNET: Q92772
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human CDKL2 sequence peptide Cat. No.: PE-01BCN85
Antibody Immunogen Sequence: CLSDDSGADLPQMEHQH
Antibody Immunogen Description: Corresponds to amino acid residues L478 to H493; C-terminus
Production Method: Corresponds to amino acid residues L478 to H493; C-terminus
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 52-57 kDa.
Related Product 1: CDKL2-CT blocking peptide
Scientific Background: CDKL2 (KKIAMRE) is a protein-serine/threonine kinase of the CMGC group and CDKL family. It is likely that phosphorylation at Y161 is required for catalytic activity and phosphorylation at Y15 is inhibitory based on homology with other CDK's. It is induced when cells are stimulated with epidermal growth factor. It may play a role in signal transduction and differentiation. It has been found to have a role in memory and learning. CDKL2 may be an oncoprotein (OP). It has been identified as a novel potent promoter for epithelial-mesenchymal transition and breast cancer progression (PubMed: 25333262). CDKL2 stimulated primary tumour formation and metastasis in a breast cancer xenograft model. It is expressed at significantly higher levels mesenchymal human breast cancer cell lines than in epithelial lines, and its over-expression/amplification in human breast cancers is correlated with shorter disease-free survival.